|1.||Higashida, Randall T: 2 articles (08/2003 - 05/2003)|
|2.||Schulz, Gregory A: 2 articles (08/2003 - 05/2003)|
|3.||Wechsler, Lawrence R: 2 articles (08/2003 - 05/2003)|
|4.||Firszt, Carolyn M: 2 articles (08/2003 - 05/2003)|
|5.||Rowley, Howard A: 2 articles (08/2003 - 05/2003)|
|6.||Furlan, Anthony J: 2 articles (05/2003 - 01/2002)|
|7.||Goldhaber, S Z: 2 articles (07/2001 - 01/2000)|
|8.||Kotb, Essam: 1 article (05/2014)|
|9.||Carrion, Geneive: 1 article (01/2012)|
|10.||Pisapia, Jared M: 1 article (01/2012)|
09/01/1999 - "Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. "
02/15/1996 - "Sequential electrocardiograms for admission to 36 hours in 358 patient s with acute myocardial infarction (AMI) from the Pro-urokinase In Myocardial Infarction trial were assessed. "
08/01/1995 - "In a multicenter observational study with core facilities for angiographic and laboratory analysis, 101 patients with acute myocardial infarction were enrolled and given a low dose bolus of rt-PA (5 to 10 mg) followed by a 90-min infusion of pro-urokinase (40 mg/h). "
12/15/1991 - "The Pro-Urokinase for Myocardial Infarction Study Group."
10/01/1999 - "Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration."
02/01/1999 - "Profile of recombinant pro-urokinase given by intraarterial versus intravenous routes of administration in a canine thrombosis model."
05/01/1997 - "Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model."
03/01/1997 - "The fibrinolytic properties of M23 and saruplase were compared in anaesthetized dogs with femoral artery and saphenous vein thrombosis. "
12/15/1991 - "In a rabbit femoral artery thrombosis model infusion of saruplase (3 - 12 mg/kg, 60 min) caused a dose-dependent thrombolysis. "
10/01/1990 - "Infusion of saruplase (21.5 micrograms/kg.min) for 60 min significantly increased the 125J-fibrinolysis to 36.8 +/- 3.7% and the reduction of the thrombus weight to 69.9 +/- 2.1%. "
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
09/01/1994 - "Safety and efficacy of the thrombolytic agent pro-urokinase (pro-UK) in the treatment of deep vein thrombosis of the lower limbs (DVT) have been investigated in an open, uncontrolled, pilot study. "
03/01/1997 - "The maximal dissolution of 125I-fibrin in the venous thrombosis model was 91 +/- 1% in M23- and 88 +/- 5% in saruplase-treated animals. "
09/01/1994 - "A pilot study of pro-urokinase in the treatment of deep vein thrombosis."
03/01/1997 - "A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs."
01/01/1998 - "Newer molecules such as pro-urokinase, saruplase, alteplase, K1K2Pu and staphylokinase have shown promise in animal models of arterial and venous thrombosis and also in pilot scale clinical studies in patients with myocardial infarction. "
01/01/2002 - "The clinical efficacy and safety of IA thrombolysis with the selective thrombolytic r-pro-urokinase (r-pro-UK) has been demonstrated in two randomized acute stroke treatment trials, PROACT I and PROACT II. However, IA pro-UK is not yet FDA approved, and it is not known if IA thrombolysis with other agents would have the same results. "
01/01/2002 - "The role of recombinant pro-urokinase (r-pro-UK) and intra-arterial thrombolysis in acute ischaemic stroke: the PROACT trials. "
08/28/1997 - "Studies are under way to determine whether t-PA can be administered with an acceptable margin of safety within 5 hours of stroke, to evaluate the therapeutic benefits of intraarterial pro-urokinase, and to assess the use of magnetic resonance spectroscopy to identify which patients are most likely to benefit from thrombolysis. "
08/01/2003 - "Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS."
06/01/1998 - "Intra-arterial pro-urokinase in ischemic stroke."
|5.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/01/1998 - "PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. "
05/01/2003 - "The PROACT II study demonstrated a significant benefit from treatment with intra-arterial pro-urokinase (r-proUK) in patients with middle cerebral artery occlusion treated within 6 hours of stroke onset. "
01/01/1998 - "To test the safety and recanalization efficacy of intra-arterial local delivery of plasminogen activators in acute ischemic stroke, a randomized trial of recombinant pro-urokinase (rpro-UK) versus placebo was undertaken in patients with angiographically documented proximal middle cerebral artery occlusion. "
|2.||Urokinase-Type Plasminogen Activator (Urokinase)
|3.||Plasminogen Activators (Plasminogen Activator)
|6.||Tissue Plasminogen Activator (Alteplase)
|7.||Fibrinolytic Agents (Antithrombotic Agents)
|8.||Staphylococcus aureus auR protein (staphylokinase)